{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deaf+Blind", "query": { "condition": "Deaf Blind" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deaf+Blind&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T01:50:42.543Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01109576", "title": "Workshops for Veterans With Vision and Hearing Loss", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Deafness", "Blindness" ], "interventions": [ { "name": "DSL Workshop", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 13, "start_date": "2011-11", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2015-09-29", "last_synced_at": "2026-05-22T01:50:42.543Z", "location_count": 2, "location_summary": "Decatur, Georgia • Portland, Oregon", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01109576" }, { "nct_id": "NCT05676034", "title": "AMX0035 in Adult Patients With Wolfram Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Wolfram Syndrome" ], "interventions": [ { "name": "AMX0035", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amylyx Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 12, "start_date": "2023-03-03", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-05-22T01:50:42.543Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05676034" }, { "nct_id": "NCT05158296", "title": "Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Retinitis Pigmentosa", "Usher Syndrome Type 2", "Deaf Blind", "Retinal Disease", "Eye Diseases", "Eye Diseases, Hereditary", "Eye Disorders Congenital", "Vision Disorders" ], "interventions": [ { "name": "Ultevursen", "type": "DRUG" }, { "name": "Sham-procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Laboratoires Thea", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 7, "start_date": "2021-12-08", "completion_date": "2022-10-12", "has_results": true, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-05-22T01:50:42.543Z", "location_count": 10, "location_summary": "San Diego, California • San Francisco, California • Miami, Florida + 7 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05158296" }, { "nct_id": "NCT05537220", "title": "Oral N-acetylcysteine for Retinitis Pigmentosa", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Retinitis Pigmentosa" ], "interventions": [ { "name": "N-acetylcysteine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 485, "start_date": "2023-10-11", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-05-22T01:50:42.543Z", "location_count": 24, "location_summary": "Davis, California • Los Angeles, California • San Francisco, California + 21 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05537220" }, { "nct_id": "NCT05176717", "title": "Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Retinitis Pigmentosa", "Usher Syndrome Type 2", "Deaf Blind", "Retinal Disease", "Eye Diseases", "Eye Diseases, Hereditary", "Eye Disorders Congenital", "Vision Disorders" ], "interventions": [ { "name": "QR-421a", "type": "DRUG" }, { "name": "Sham-procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Laboratoires Thea", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 5, "start_date": "2021-12-15", "completion_date": "2022-08-02", "has_results": true, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-05-22T01:50:42.543Z", "location_count": 2, "location_summary": "Dallas, Texas • Madison, Wisconsin", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176717" }, { "nct_id": "NCT02435940", "title": "Inherited Retinal Degenerative Disease Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Eye Diseases Hereditary", "Retinal Disease", "Achromatopsia", "Bardet-Biedl Syndrome", "Bassen-Kornzweig Syndrome", "Batten Disease", "Best Disease", "Choroidal Dystrophy", "Choroideremia", "Cone Dystrophy", "Cone-Rod Dystrophy", "Congenital Stationary Night Blindness", "Enhanced S-Cone Syndrome", "Fundus Albipunctatus", "Goldmann-Favre Syndrome", "Gyrate Atrophy", "Juvenile Macular Degeneration", "Kearns-Sayre Syndrome", "Leber Congenital Amaurosis", "Refsum Syndrome", "Retinitis Pigmentosa", "Retinitis Punctata Albescens", "Retinoschisis", "Rod-Cone Dystrophy", "Rod Dystrophy", "Rod Monochromacy", "Stargardt Disease", "Usher Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "Foundation Fighting Blindness", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20000, "start_date": "2014-06", "completion_date": "2037-06", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-05-22T01:50:42.543Z", "location_count": 1, "location_summary": "Columbia, Maryland", "locations": [ { "city": "Columbia", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02435940" }, { "nct_id": "NCT00004345", "title": "Study of Dietary N-3 Fatty Acids in Patients With Retinitis Pigmentosa and Usher Syndrome", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Usher Syndrome", "Retinitis Pigmentosa" ], "interventions": [], "intervention_types": [], "sponsor": "National Center for Research Resources (NCRR)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "0 Years", "maximum_age": null, "sex": "ALL", "summary": "0 Years and older" }, "enrollment_count": 100, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-05-22T01:50:42.543Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004345" }, { "nct_id": "NCT05085964", "title": "An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Retinitis Pigmentosa", "Usher Syndrome Type 2" ], "interventions": [ { "name": "RNA antisense oligonucleotide for intravitreal injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Laboratoires Thea", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 21, "start_date": "2021-09-16", "completion_date": "2022-10-18", "has_results": true, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-05-22T01:50:42.543Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05085964" }, { "nct_id": "NCT06938542", "title": "Palliative Care Needs of Children With Rare Diseases and Their Families", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Trisomy 13 Syndrome", "Arthrogryposis Congenita Multiplex With Intestinal Atresia", "Asparagine Synthetase Deficiency", "CHARGE Syndrome", "Early Infantile Epileptic Encephalopathy", "FOXG1 Syndrome", "KBG Syndrome", "Noonan Syndrome", "Severe Hemophilia A", "Short Bowel Syndrome", "Beta-Propeller Protein-Associated Neurodegeneration", "Brain Injury of Prematurity With Periventricular Leukomalacia", "Chromosome 17p13.3 Microdeletion Syndrome", "Chromosome 1q43-1q44 Deletion", "Cockayne Syndrome", "Congenital Diaphragmatic Hernia", "End-Stage Renal Disease With Cloacal Anomaly", "Mitochondrial Depletion Disorder", "Severe Factor VII Deficiency" ], "interventions": [ { "name": "Family Centered pediatric palliative care for family caregivers of children with rare diseases.", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "99 Years", "sex": "ALL", "summary": "12 Months to 99 Years" }, "enrollment_count": 480, "start_date": "2025-10-02", "completion_date": "2029-08-02", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-05-22T01:50:42.543Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06938542" }, { "nct_id": "NCT02065011", "title": "A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Usher's Syndrome" ], "interventions": [ { "name": "Blood draw for the laboratory assessment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2013-09-12", "completion_date": "2031-06-13", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-05-22T01:50:42.543Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065011" } ] }